This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

October 26-28, 2021
2:30pm - 5:00pm CETOnline Training Course

June 8-10 Training Course Schedule

12:00pm - 12:30pm EST / 9:00am - 11:30am PCT / 5:00pm - 7:30pm GMT / 6:00pm - 8:30pm CET
This course will also be available on-demand for anyone with a time conflict.

(12:00pm - 12:30pm EST)
Introduction to Speaker and Workshop 

  • Welcome words
  • Speaker introduction
  • Content of the Workshop
  • What is a conjugate?

(12:30pm - 1:00pm EST)
Introduction to Therapeutic Oligonucleotide Conjugates I 

  • Different types of oligonucleotides and their mode of action.
  • Why do we need Oligonucleotide conjugates?
  • Do we always need Oligonucleotide conjugates?
  • Clinical status of Oligonucleotide conjugates

(1:00pm - 1:15pm EST)
Break

(1:15pm - 1:45pm EST)
Introduction to Therapeutic Oligonucleotide Conjugates II

  • Disease Areas of interest
  • Ligand opportunities
  • Lipid, Antibody, GalNAc siRNA conjugates
  • Lipid, Antibody, GalNac ASO conjugates
  • Peptide ASO, SSO conjugates
  • Antibody SSO conjugates
  • Two choices in Oligonucleotide conjugate synthesis

(1:45pm - 2:15pm EST)
Oligonucleotide Conjugate Synthesis

  • Solid phase synthesis of conjugates
  • Solution phase synthesis of conjugates

(2:15pm - 2:30pm EST)
Q&A and Group Discussion

October 26-28 Training Course Schedule

8:30am - 11:00am EST / 1:30pm - 4:00pm GMT / 2:30pm - 5:00pm CET / 9:30pm - 12:00am JST / 5:30am - 7:00am PCT
This course will also be available on-demand for anyone with a time conflict.

(8:30am - 9:00am EST)
Introduction to Speaker and Workshop 

  • Welcome words
  • Speaker introduction
  • Content of the Workshop
  • What is a conjugate?

(9:00am - 9:30am EST)
Introduction to Therapeutic Oligonucleotide Conjugates I 

  • Different types of oligonucleotides and their mode of action.
  • Why do we need Oligonucleotide conjugates?
  • Do we always need Oligonucleotide conjugates?
  • Clinical status of Oligonucleotide conjugates

(9:30am - 9:45am EST)
Break

(9:45am - 10:15am EST)
Introduction to Therapeutic Oligonucleotide Conjugates II

  • Disease Areas of interest
  • Ligand opportunities
  • Lipid, Antibody, GalNAc siRNA conjugates
  • Lipid, Antibody, GalNac ASO conjugates
  • Peptide ASO, SSO conjugates
  • Antibody SSO conjugates
  • Two choices in Oligonucleotide conjugate synthesis

(10:15am - 10:45am EST)
Oligonucleotide Conjugate Synthesis

  • Solid phase synthesis of conjugates
  • Solution phase synthesis of conjugates

(10:45am - 11:00am EST)
Q&A and Group Discussion